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Background: Chronic obstructive pulmonary disease (COPD) can be diagnosed when the
FEV1/FVC ratio is below 70%, according to global initiative for chronic obstructive lung
disease (GOLD). COPD is known as a disease which is frequently under-diagnosed. However,
there is a risk of over diagnosis when this diagnostic threshold is applied among the elderly.
Aims: To contribute to the discussion about the criteria for diagnosing COPD, by describing
lung function and pulmonary symptoms in a population aged 60 years or more, and in
particular the changes in the mean and 5% percentile of the FEV1/FVC ratio by increasing
age.
Methods: A cross sectional population-based study was performed in the city of Tromsø,
Norway, in 2001–2002. Spirometry was performed in 4102 people 60 years and older (54.6%
women), who also filled in a questionnaire.
Results: Decreased FEV1% predicted and FEV1/FVC ratio were associated with smoking,
increasing age, and reported pulmonary and cardiovascular diseases. Dyspnoea and
coughing were also strongly associated with smoking and reported pulmonary and
cardiovascular diseases, but coughing did not become more frequent by increasing age. In
never smokers aged 60–69 years the frequency of FEV1/FVC ratioo70% was approximately
7% compared to 16–18% in those 70 years or more (po0.001). FEV1/FVC ratioo70% among
never smokers aged 60–69 years was just as frequent as FEV1/FVC ratio o65% in never
smokers older than 70 years.
Conclusion: Adjustments of the GOLD criteria for diagnosing COPD are needed, and FEV1/
FVC ratios down to 65% should be regarded as normal when aged 70 years and older.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
64 59 08; fax:+47 77 64 48 31.
it.no (A. Medbø).
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Chronic obstructive lung disease (COPD) is increasing in the
whole world, and it is estimated to be the third leading
cause of death, and the fifth leading cause of disability in
the world within 20–50 years.1–3 Smoking is responsible for
the majority of cases,1,4,5 and due to the cumulative effect
of years of smoking, the prevalence of COPD increases
with age.6
Spirometry is recommended in the diagnosis and evalua-
tion of COPD,1,7,8 and Global initiative for chronic obstruc-
tive lung disease (GOLD) has defined COPD to be present
when the FEV1/FVC ratio is below 70%.
1 Also ATS-ERS and
NICE guidelines use FEV1/FVCp70% post-bronchodilator as a
criterion for diagnosing COPD, regardless of age.9 It is,
however, well known that the FEV1/FVC ratio decreases with
increasing age,6 and that the use of a fixed ratio for all ages
may lead to misclassifications, under diagnosis in the
younger population and over diagnosis among the el-
derly.7,10–13 To contribute to the decision on valid cut-off
points for the FEV1/FVC ratio in the diagnosis of COPD, we
have studied lung function and pulmonary symptoms in a
general population aged 60 years or more.
Methods
Subjects
The survey took place in Tromsø, a city in the northern part
of Norway with about 61 000 inhabitants, and 7842 inhabi-
tants aged 60 years or more (January 2001). There is little
occupational or environmental pollution in Tromsø.
This fifth cross sectional ‘‘Tromsø Study’’ was conducted
by The University of Tromsø in cooperation with the National
Health Screening Service. It started March 2001 and ended
February 2002.
In the fourth survey in 1994, all citizens aged 25 years or
more (37 558 persons) were invited to a brief examination.
Those who were 55–74 years of age, and a random sample of
5–10% of the others between 25–84 years, were also asked
to take part in a second, more detailed medical examination
(phase 2); 7965 persons (77%) met. All the phase 2
participants from the fourth survey, who still lived in
Tromsø, were eligible to participate in the two phases of
the fifth study, and met twice with a few weeks gap. In
addition all inhabitants aged 60 and 75 years were invited.
In subjects aged 60 years and above, a total of 5328 subjects
were eligible and 4713 (88.5%) attended phase one, and
4519 (85%) attended also phase two. Spirometry was
included for the first time in the Tromsø Study, and was
performed in 4102 subjects, 90% of the attendees and 77% of
the eligible for participation. Absence of staff and technical
problems were reasons for spirometry not being performed
in 10% of the attendees.
Examinations
A questionnaire including smoking habits and different
symptoms and diseases, were sent by mail together with
the invitation to participate. Spirometry was carried out
with the use of one spirometer only, a ‘‘Sensormedics Vmax20’’. The American Thoracic Society-criteria for spirometry
testing14 were followed. Calibration of the instrument was
performed every morning and on the machines demand.
Three trained technicians shared the conducting of the
spirometry. The subjects were sitting, using a nose clip, and
were instructed to blow as long as possible, and at least for
6 s. The participants took a full inspiration before inserting
the mouthpiece (‘‘open circuit’’). At least three exhalations
where required. The difference between best and next best
FEV1 and FVC should not exceed 5% or 200ml, whichever was
the greater. Reversibility test was not performed. Current
drug therapy was not interrupted before the test. Height
was measured barefoot.
Quality test
In week 41 and 42 in 2001 an inter- and intra observer
agreement test was done with two of our three technicians
(A and B) and 80 participants. It implied repeated testing
both weeks. The two technicians were blinded for each
other’s results.
Statistical analysis
Spirometric results and symptoms were analysed according
to sex, age, smoking habits and reported lung and
cardiovascular disease. Those who reported to be never
smokers, and not having asthma, bronchitis, angina pec-
toris, myocardial infarction or stroke, were classified as
healthy never smokers. FEV1% predicted and FVC% predicted
were calculated based on the Norwegian equation devel-
oped by Langhammer and co-workers.15 Linear regression
models and independent samples T-tests, and Chi-square
test were used to check whether differences between
groups were statistically significant. The mean and the
5% percentile of FEV1/FVC% in healthy never smokers
were compared with the expected mean and lower limit
of normal (LLN ¼ the estimated 5% percentile) accord-
ing to an equation developed by Enright and co-workers.7
Inter- and intra-observer agreement were evaluated in 2 2
tables with FEV1/FVCX70% as threshold, using Kappa
statistics and Bland–Altman plots. The SPSS 14.0 for
Windows (SPSS inc, Chicago, Illinois, USA) was used in the
statistical analyses.
The Regional Committee for Medical Research Ethics
approved the study. All the participants gave informed
written consent.
Results
Spirometry was performed in 4102 persons aged 60 years or
more, 2269 women and 1833 men. At the completion of the
data collection, 25 women and 12 men had withdrawn their
consent to participate. Ninety women and 21 men (2.7% of
all) were excluded due to inadequate performance (of these
84 women and 20 men blew less than 3 s). The 62 women and
12 men who exhaled 3–6 s (where FVC did not exceed FEV6),
were included in the analysis, which in total comprised of
2154 women aged 60–89 and 1800 men aged 60–85 years
(Table 1). Significantly more women (46%) than men (18%)
were never smokers (po0.001) (Table 1 and 2). Asthma and
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Table 1 Characteristics of the participants in the study.
Women Men
n % n %
Total 2154 54.5 1800 45.5
Age (years)
60–64 598 27.7 434 24.1
65–69 554 25.7 523 29.0
70–74 507 23.6 442 24.6
75–79 382 17.7 306 17.0
80+ 113 5.2 95 5.3
Smoking habita
Never smoker 999 46.9 327 18.3
Ex-smoker 633 29.7 1043 58.3
Current smoker 498 23.4 419 23.4
Pack-years
smokedb
o10 401 42.2 331 26.4
10–19 275 29.0 377 30.1
20–29 185 19.7 270 21.5
30+ 85 9.1 275 22.0
Reported diseases
Cardiovascular 325 15.1 491 27.3
Myocardial
Infarction
109 5.1 264 14.7
Cerebral Stroke 87 4.0 110 6.1
Angina 214 9.9 283 15.7
Pulmonary 303 14.1 219 12.2
Asthma 233 10.8 158 8.8
Chronic
Bronchitis
133 6.2 98 5.4
aMissing data in 23 women and 11 men.
bMissing data in 185 women and 209 men.
Table 2 Smoking habits in the participants.
Never
smokers
Previous
smokers
Current
smokers
Women (all) ðn ¼ 999Þ ðn ¼ 633Þ ðn ¼ 498Þ
46.4 29.4 23.1
60–69 years 42.9 29.2 27.0
70 years or more 50.9 29.6 18.7
Men (all) ðn ¼ 327Þ
ðn ¼ 1043Þ ðn ¼ 419Þ
18.2 57.9 23.3
60–69 years 20.7 53.2 25.6
70 years or more 15.3 63.3 20.6
Numbers given in %.
Missing in 23 women and 11 men.
Lung function testing in the elderly 1099bronchitis were reported in 14.1% women and 12.2% men
ðp ¼ 0:053Þ, whilst cardiovascular diseases were reported by
15.1% women and 27.3% men (po0.001).In women mean FEV1% predicted was almost identical in
all age groups, and FVC% predicted was above 90 regardless
of age and smoking status, except for current smokers
(Table 2). In men the FEV1% predicted and FVC% predicted
decreased significantly both by increasing age and by
smoking habit (po0.001, Table 3). The FEV1/FVC ratio
decreased significantly by increasing age in both sexes
(po0.001).
All the three lung function measures were significantly
lower in both sexes when chronic pulmonary disease was
reported than in those who neither reported pulmonary nor
cardiovascular disease (po0.001, Table 2). Reporting
cardiovascular disease was significantly associated with
reduced lung function in men (po0.001), while only FEV1%
predicted ðp ¼ 0:009Þ and FVC% predicted ðp ¼ 0:003Þ were
reduced in women with such diseases (Table 3).
Dyspnoea when walking slowly on level ground was
reported more frequently by women than by men, but only
significantly in those with pulmonary diseases (p ¼ 0:004,
Table 4). Daily coughing in periods of the year was reported
more frequently in men than in women (po0.001), and
was especially increased in smokers and those who
reported asthma or chronic bronchitis. This symptom was,
however, reported by more than 10% of healthy never
smokers (Table 4).
The frequency of FEV1/FVC ratio o70% increased by
increasing age in both sexes, irrespective of smoking
habits (Table 5). A fifteen-fold higher frequency was found
among current smoking men aged 70 years or more (61.5%)
than among healthy never smoking men aged 60–69
years (3.9%). In never smokers aged 60–69 years the
frequency of FEV1/FVC ratioo70% was approximately 7%,
compared to 16–18% in those 70 years or more (po0.001).
FEV1/FVC ratioo70% among never smokers aged 60–69 years
was just as frequent as FEV1/FVC ratio o65% in never
smokers older than 70 years. When applying a FEV1/FVC
limit of 65% among those above 70 years of age, the
prevalence of COPD would be reduced from 26.2 to 13.2% in
all women, and from 38.1 to 20.5% in all men (Tables 5
and 6). The prevalence of cough and dyspnoea were
inversely correlated with lung function in the oldest age
group (Table 7).
Among the healthy never smoking women, the mean
FEV1/FVC ratio fell from 78.4% in the 60–64 years age group,
to 71.4% among those aged 80 years or more (Fig. 1). The fall
was somewhat steeper than expected from Enright’s
equations. The corresponding numbers for men were 78.9%
and 74.7%, and the mean FEV1/FVC ratio was higher than
expected from this equation (Fig. 2). The 5% percentile of
the FEV1/FVC ratio also dropped more steeply among the
women than expected from the Enright equations (Fig. 3),
and was about 65% in women aged 70 years or more, and 60%
in women older than 80 years. Similar results were found
among the men, but these are less valid due to a lower
number of subjects (Fig. 4).
The inter-observer and intra-observer agreement in
measuring FEV1/FVC higher or lower than 70%, showed
Kappa values in the range 0.77–0.92 (mean 85.5). Three out
of four Kappa values were above 0.80 both in those aged
60–69 years (mean 0.85) and those who were older (mean
0.83). The Bland–Altman plots were homogenous, and are
shown in Fig. 5.
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Table 3 Spirometric results in 2154 women and 1800 men by age groups, smoking status, reported diseases, and for the
healthy never smokers.
Women Men
FEV1% predicted FVC%
predicted
FEV1/FVC
(%)
FEV1%
predicted
FVC%
predicted
FEV1/FVC
(%)
n Mean Mean Mean n Mean Mean Mean
All 2154 84.5 91.3 74.0 1800 81.4 89.6 72.4
Age groups
60–65 598 84.9 91.2 75.4 434 85.7 92.0 74.8
65–69 554 84.2 90.8 74.5 532 82.7 90.6 73.0
70–74 507 84.7 91.8 73.4 442 80.1 89.2 71.3
75–79 382 84.1 91.3 72.4 306 76.7 86.1 70.5
80+ 113 85.4 92.8 71.9 95 75.5 85.5 69.4
Smoking habit
Never smoker 994 88.0 92.9 75.7 327 87.0 91.5 76.0
Ex-smoker 629 84.7 91.6 73.8 1035 81.8 89.4 72.8
Current smoker 498 77.3 87.9 70.5 417 76.3 88.6 68.7
Reported
cardiovascular
diseases
Myocardial
infarction
109 81.2 88.3 73.3 261 74.6 83.8 70.9
Cerebral stroke 87 80.2 86.1 74.5 108 75.1 84.4 70.7
Angina pectoris 214 81.8 88.0 74.2 283 76.8 85.9 71.1
Reported
pulmonary
disease
Asthma 233 71.5 82.4 68.8 157 66.1 81.0 64.8
Chronic
bronchitis
133 69.0 81.1 67.4 97 66.3 80.1 64.7
Healthy never
smokers
730 89.6 94.3 76.0 235 89.3 92.8 77.8
The Norwegian A. Langhammer reference values are used.
A. Medbø, H. Melbye1100Discussion
The study confirms what is known from previous epidemio-
logical surveys7,11,12,16–18 that the FEV1/FVC ratio falls
significantly after the age of 60. FEV1/FVCo70% was 50%
more frequent in women older than 70 years compared to
those aged 60–69 years (26.2% and 17.4%, respectively,
Table 5). The corresponding increase in men was 80%. The
relative increase was much higher among healthy never
smokers, approximately 170% in both sexes, than among
current smokers, 30% in women and 60% in men. Does this
increase in the frequency of FEV1/FVCo70% among healthy
never smokers by increasing age reflect an increasing
prevalence of COPD, or mainly the normal ageing process?
To be a smoker is the most important reason for getting
COPD.1 In our material women aged 70 years or more were
8.0% more frequently never smokers and 8.3% less fre-
quently current smokers than those who were in the sixties
(Table 2). In men, current smokers also became less
frequent by increasing age. One may question whetherthere really is an increase in the prevalence of COPD by
increasing age, particularly in women.
Only small differences occurred in reported cough and
dyspnoea between subjects under and over 70 years of age,
except for dyspnoea on walking slowly on level ground
(po0.001 women and p ¼ 0:005 men, Table 4). The
tendency of less coughing in the oldest age group among
women may also indicate that the prevalence of COPD did
not increase.
The reduction in lung function can to some degree be
explained by the structural changes that take place in the
airways with increasing age, including dilatation of the
alveoli and loss of supportive tissue in the peripheral airways
called ‘‘senile emphysema’’.13 Another aspect of normal
ageing is loss of muscular tissue generally and reduced
physical endurance. The elderly suffer, in addition, from
other diseases, co-morbidities which may influence the lung
function.7 Heart failure, in particular, is known to be
associated with reduced spirometric values, including the
FEV1/FVC ratio in severe cases.
19
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Table 4 Reported symptoms in women and men by age-groups, smoking habits and reported diseases.
Women Men
Dyspnoea
on slow
walkinga
Dyspnoea
on quick
walkingb
Cough
daily in
periodsc
Chronic
coughd
Dyspnoea
on slow
walkinga
Dyspnoea
on quick
walkingb
Cough
daily in
periodsc
Chronic
coughd
All 4.1 48.5 16.1 10.7 3.1 46.3 22.6 14.5
Age groups
60–69 3.5 47.2 16.5 10.7 2.6 45.1 22.0 13.8
70+ 5.7 51.1 14.6 10.4 4.3 48.5 23.3 15.9
Smoking habit
Never smoker 4.1 45.7 12.3 8.4 1.5 33.3 15.0 9.8
Ex-smoker 3.9 50.7 13.6 9.8 3.0 47.3 17.8 11.6
Current
smoker
4.2 51.4 26.9 16.9 4.3 53.7 40.3 25.1
Reporting
cardiovascular
diseases
8.9 70.5 15.4 10.5 7.5 64.0 22.6 14.9
Reporting
pulmonary
disease
11.9 71.3 41.3 29.7 4.6 69.4 46.1 35.6
Healthy never
smokers
2.1 37.8 10.4 7.1 1.3 28.1 12.3 8.1
Numbers given in %.
aDyspnoea when walking slowly on level ground.
bDyspnoea when walking quickly on level ground or slightly upwards.
cDaily coughing in periods of the year.
dCoughing more than three months during the last 2 years.
Table 5 Prevalence (%) of FEV1/FVCo70% by age and smoking habits in women and men.
Healthy never smokers Never smokers Previous smokers Current smokers All
Women
60–69 years 6.2 7.0 17.0 35.0 17.4
70 years or more 16.8 18.0 28.0 46.0 26.2
Men
60–69 years 3.9 7.6 18.3 37.1 21.1
70 years or more 10.8 16.3 35.2 61.5 38.1
Table 6 Prevalence (%) of FEV1/FVCo65% in those 70 years and older, by age and smoking habits in women and men.
Prevalence (%) of FEV1/FVCo65%
Healthy never smokers Never smokers Previous smokers Current smokers All
Women
70 years or more
FEV1/FVC o65%
4.9 6.7 13.5 31.0 13.2
Men
70 years or more
FEV1/FVC o65%
2.4 7.8 17.8 37.4 20.5
Lung function testing in the elderly 1101
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Table 7 Prevalence (%) of reported symptoms by FEV1/FVC in women and men above 70 years of age.
n Dyspnoea on slow
walkinga
Dyspnoea on quick
walkingb
Cough daily in
periodsc
Chronic
coughd
FEV1/FVC
o65% 305 8.9 65.6 32.8 25.2
65–69% 279 6.1 54.8 23.3 13.3
70% or more 1261 3.9 45.0 14.0 9.8
aDyspnoea when walking slowly on level ground.
bDyspnoea when walking quickly on level ground or slightly upwards.
cDaily coughing in periods of the year.
dCoughing more than three months during the last 2 years.
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Figure 1 Mean FEV1/FVC ratios in 730 never smoking women,
without reported pulmonary or cardiovascular disease (healthy
never smokers), by age group, compared with expected values
according to the reference equations of Enright.
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Figure 2 Mean FEV1/FVC ratios in 235 never smoking men,
without reported pulmonary or cardiovascular disease (healthy
never smokers), by age group, compared with expected values
according to the reference equations of Enright.
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Figure 3 The 5% percentile of FEV1/FVC in 730 never smoking
women, without reported pulmonary or cardiovascular disease
(healthy never smokers), by age group, compared with
expected LLN (lower limit of the normal range ¼ fifth percen-
tile) values according to the reference equations of Enright.
A. Medbø, H. Melbye1102COPD is certainly under-diagnosed in the society. Johan-
nessen and co-workers found that only 43% of subjects with
COPD had been diagnosed by a doctor, and the majority of
these had a GOLD stage 2–3 COPD.20 Only 5% of thoseclassified as having GOLD stage 1 (FEV1/FVCo70% and
FEV1480% predicted) had been diagnosed in the health
care system as having COPD in a Swedish survey.21 Cautions
should be made in classifying persons fulfilling GOLD stage 1
criteria as having COPD. The clinical importance of GOLD
stage 1 has been questioned by a recent study, in which no
increased risk of death was associated with such a mild
degree of ‘‘COPD’’.22
It seems obvious that we need a lower spirometric
threshold when diagnosing COPD in the elderly. A threshold
of 65% after the age of 70 can be suggested on the basis of
our results (Table 6, Figs. 3 and 4). The tendency of lower
frequency of ‘‘COPD’’ among the oldest age group of healthy
never smokers (which was not statistically significant) can
probably be explained by a ‘‘healthy survivor’’ effect.23 A
fixed ratio used as a threshold in a large age group can never
be more than ‘‘a rule of the thumb’’. Comparison with a LLN
(lower limit of normal) age-related curve may be a good
alternative, in order to improve the diagnostic precision.
However, diagnostic thresholds will always be arbitrary and
other explanations than COPD should always be considered
when a borderline result or moderate obstruction is
found. New thresholds should be evaluated against clinical
usefulness.
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Lung function testing in the elderly 1103It is important to avoid medicalisation.24 Many elderly
people use five to 10 types of medicines already. Over
diagnosis of COPD may lead to unnecessary use of pulmonary
medication, and an additional diagnosis could increase their
feeling of being unfit.
The results are probably representative of the elderly
population in Tromsø. The attendant rate in phase 2 was 85%Men
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Figure 4 The 5% percentile of FEV1/FVC in 235 never smoking
men, without reported pulmonary or cardiovascular disease
(healthy never smokers), by age group, compared with
expected LLN (lower limit of the normal range ¼ fifth percen-
tile) values according to the reference equations of Enright.
Estimation could not be made in those older than 80 years, due
to a low number of subjects ðn ¼ 14Þ.
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Figure 5 Bland-Altman plots of inter- and intra observer variabilit
weeks. (A) FEV1/FVC week 1.Technician A versus technician B. (B) F
week 1 versus week 2 for technician A. (D) FEV1/FVC week 1 versusand the 10% who did not perform a spirometry due to
technical problems and absence of staff were not subject to
selection bias. There may be some bias in our material
because we did not invite non-participants from earlier
studies. We have information on responders and non-
responders to a questionnaire that was handed out at the
screening in an earlier Tromsø survey.25 The subjects who
returned the questionnaire tended to be married, non-
smoking, and reporting respiratory symptoms less often than
non-responders. The non-responders did otherwise not vary
much from the responders. A mortality follow-up study of
persons invited to a cardiovascular disease survey in five
areas in Norway, has shown a mortality rate 3.7 times higher
(age-adjusted all-cause mortality rate) in non-attending
women and a 2.2 times higher mortality rate in non-
attending men compared to attendees.26 Our results might
therefore be a little higher than in the total population.
The mean FVC% predicted did not reach 100%, not even in
healthy never smokers. When using the equation from
European Community for Steele and Coal,14 the mean
FVC% predicted were 107% and 98% in women and men,
respectively. The inclusion criterions to the reference
material of Langhammer et al.15 are strict, not allowing
any reported respiratory symptoms like wheezing and
breathlessness during the last 12 months. Only 236 never
smokers older than 60 years were included. The reference
values may be too strict for our elderly population.
We are confident with the quality of the spirometry. There
were only three technicians involved, and only one
spirometer was used. The Kappa-values for the inter- and
intra-observer agreements were close to optimal and theFEV1/FVC week 2 technician A
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y test of FEV1/FVCo70% for two technicians in two subsequent
EV1/FVC week 2.Technician A versus technician B. (C) FEV1/FVC
week 2 for technician B.
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A. Medbø, H. Melbye1104Bland–Altman plots are homogenous (Fig. 5). The 74
subjects, who blew for more than three, but less than 6 s,
were included in the analyses. Excluding these subjects
induced only minimal and insignificant changes of the
results.
Higher FEV1/FVC% values were found among the healthy
never smoking men than expected on the basis of Enright’s
material (Fig. 2). One reason for this may be the less strict
inclusion criterions in Enright’s study, as people who had
smoked up to five pack-years also were included.
The omission of reversibility testing is a weakness of our
study. Johannessen et al. found that the prevalence of FEV1/
FVC below 70% decreased by approximately 18% after
inhalation of a beta2-agonist for subjects 60 years and
over,27 and our spirometric values would probably have been
somewhat higher if they had been based on reversibility
testing. However, the frequency in our study of FEV1/FVC
ratio less than 70% among subject 75–79 years was similar to
the frequencies found by Lundba¨ck et al.28 after reversi-
bility testing in subjects aged 76–77 years, both in smokers
and never smokers. The negative effect of not doing
reversibility testing may to some degree have been reduced
by the fact that on-going medication, including anti-asthma
medicines, had not been interrupted.
The FEV1/FVC ratio is a practical indicator of the lung
function. It is easily measured, and can be used without the
need of reference equations. The application of the 70%
threshold in all ages is, however, an oversimplification, as
previously stated by Enright, Falaschetti and Hardie.7,11,12
Adjustments have to be done to make the measure clinically
useful and credible. A threshold of 65% after the age of 70
can be suggested on the basis of our results.Acknowledgements
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